A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Non-Healing Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, randomized, controlled, clinical study to establish clinical based evidence of PRP Concepts Fibrin Bio-Matrix and compare its performance with the usual and customary practice for the treatment of Wagner 1 or 2 DFUs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Pressure Ulcers

NCT02312570

Pressure Ulcer

UNKNOWN NA

A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Venous Leg Ulcers

NCT02312518

Venous Leg Ulcers

UNKNOWN NA

Allogeneic Platelet Rich Plasma (PRP) to Treat Diabetic Foot Ulcers

NCT06680856

Diabetic Foot Ulcer Skin Lesions Allogeneic +1 more

COMPLETED PHASE1/PHASE2

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

NCT02071979

Diabetic Foot Ulcers Venous Ulcers Pressure Ulcers

TERMINATED NA

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

NCT06810726

Diabetic Foot Ulcer Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus (T2DM) +3 more

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, single-blind, controlled, multi-center study for subjects undergoing DFU treatment. Qualified subjects will be randomized (1:1); test group (PRP Concepts Fibrin Bio-Matrix) and control group (usual and customary practice). The study will consist of 3 periods: a screening period, an active treatment period, and a follow-up period (if healed). Approximately 250 subjects will be enrolled. Subjects will be ≥18 years of age with a chronic Wagner grade 1 or 2 DFU (greater than 1 month duration). Each subject will be enrolled in the active treatment period for up to 12 weeks, or to closure of wound with a confirmatory visit 2 weeks after wound closure, whether such closure occurs at 12 weeks or earlier.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP Concepts Fibrin Bio-Matrix

Group Type EXPERIMENTAL

PRP Concepts Fibrin Bio-Matrix

Intervention Type DEVICE

Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice

Usual and Customary Practice

Intervention Type OTHER

Usual and customary care for non-healing wounds

Usual and customary practice

Group Type ACTIVE_COMPARATOR

Usual and Customary Practice

Intervention Type OTHER

Usual and customary care for non-healing wounds

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRP Concepts Fibrin Bio-Matrix

Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice

Intervention Type DEVICE

Usual and Customary Practice

Usual and customary care for non-healing wounds

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Standard of Care

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Medicare eligible
* A full thickness diabetic foot ulcer with a viable wound bed
* Diabetes mellitus (type I or II) that is adequately controlled
* The ulcer is greater than 4 weeks duration.
* The largest non-healing wound, if multiple wounds are present, or the single wound to be treated (index ulcer) is a Wagner 1 or 2 DFU (see Appendix for Wagner Classification) that is located on the plantar, medial, or lateral aspect of the foot (including all toe surfaces but not on the heel).
* Post-debridement, the ulcer size must be between 0.5 - 20 cm2.
* One of the following assessments was completed to confirm pedal circulation: ankle / brachial index is between 0.7 to 1.2; transcutaneous partial pressure oxygen (TcPO2) \> 30 mmHg at the ankle; or toe pressure of \>40mm Hg or a doppler waveform consistent with adequate flow in the foot (biphasic or triphasic)
* Able and willing to provide a voluntary written informed consent.
* Able and willing to wear an off-loading device or orthopedic shoe
* Able and willing to attend scheduled follow-up visits and study related exams

Exclusion Criteria

* Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator
* Wagner 3, 4, 5 DFU
* Gross clinical infection at the study ulcer site including cellulitis and osteomyelitis
* Wounds that are likely to require dressing changes more frequent than twice weekly (heavy exudates).
* Known allergy tor sensitivity to Eclipse PRP kit components (calcium chloride, calcium gluconate or acid citrate dextrose solution A (ACDA))
* Presence of Gangrene
* Active Charcot's disease as determined by clinical and radiographic examination of a non-diabetic pathophysiology (e.g., rheumatoid, radiation-related, and vasculitis related ulcers)
* Malignancy at or near the ulcer site
* Known serum albumin \< 2.5 mg/dl, Known renal failure as determined by a Creatinine \> 2.5 mg/dl, Plasma Platelet count of less than 100 x 109/L, Hemoglobin of less than 10.5 g/dL
* Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell disease, HIV
* Severe liver disease. Severe liver disease is defined as known history of chronic hepatitis or cirrhosis \&/or the following abnormal Liver Function Tests: ALT \& AST \>35, ALP \>120, PT \>12 seconds.
* Presence of additional abnormal lab values obtained within 7 days prior to the Day 0 visit determined to be clinically significant by the investigator including: WBC \>13,000/cm3 or \< 5, 000 cm3, or electrolytes that are outside the host institution's range of normal.
* Radiation therapy, chemotherapy, chronic steroid use or immunosuppressive therapy within 30 days of enrollment
* Received another investigational device or drug within 30 days of enrollment
* Received allograft, autograft or xenograft within 30 days of enrollment
* Subject has inadequate venous access for repeated blood draw required for Eclipse RPR administrations
* Subject requires or is anticipated to require interventions directed at improvement of arterial perfusion to affected area.
* Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)
* Any condition judged by the investigator that would cause the study to be detrimental to the subject
* Alcohol or drug abuse, defined as current medical treatment for substance abuse
* Pregnant or nursing women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No